POST-TEST

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Because it is universally expressed on malignant plasma cells, which of the following antigens is an attractive target for CAR T-cell-directed therapy in MM?***
   a. BCMA
   b. CD19
   c. CD33

2. **A study presented at the 2016 ASH Annual Meeting demonstrated that daratumumab _____ safely be administered via subcutaneous injection.***
   a. Could
   b. Could not

3. **Which of the following proteasome inhibitors has demonstrated activity in myeloma affecting the central nervous system?***
   a. Bortezomib
   b. Ixazomib
   c. Carfilzomib
   d. Marizomib

4. **Ibrutinib is FDA approved for the treatment of _____.**
   a. Chronic graft-versus-host disease
   b. WM
   c. Both a and b
   d. Neither a nor b

5. **Infusion-related reactions associated with the administration of daratumumab tend to persist over the course of the patient's treatment.**
   a. True
   b. False

6. **Which of the following side effects is NOT associated with ixazomib therapy?**
   a. Arthralgia
   b. Gastrointestinal toxicity
   c. Peripheral neuropathy
   d. All of the above

7. **Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.***
   a. True
   b. False

8. **The Phase III randomized ELOQUENT-2 study evaluating elotuzumab/lenalidomide/dexamethasone versus lenalidomide/dexamethasone _____ a significant improvement in progression-free survival with the addition of elotuzumab for patients with R/R MM.**
   a. Demonstrated
   b. Did not demonstrate

9. **Which of the following categories reflects the mechanism of action of isatuximab?***
   a. Anti-CD38 monoclonal antibody
   b. Anti-PD-1/PD-L1 antibody
   c. IMiD
   d. Proteasome inhibitor

10. **Recent data presented from the Myeloma X and XI trials demonstrated that lenalidomide maintenance therapy improved outcomes for transplant-eligible patients with _____.**
    a. High-risk MM
    b. Standard-risk MM
    c. Both a and b
    d. Neither a nor b

* The content of this question refers to drugs or the use of drugs that have not yet received FDA approval.